Hypertension in thoracic transplant recipients

Journal of Human Hypertension

Volumn 12, Issue 12, 1998, Pages 813-823

  Jenkins, G H ^a   Singer, D R J ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

Blood pressure; Circadian; Cyclosporin A; Dietary sodium; Immunosuppression; Transplantation

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; SODIUM ION; STEROID; TACROLIMUS; WATER;

AMBULATORY MONITORING; ARTICLE; BLOOD PRESSURE MONITORING; CIRCADIAN RHYTHM; DISEASE CLASSIFICATION; DISEASE SEVERITY; FLUID BALANCE; HEART DENERVATION; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; LUNG TRANSPLANTATION; MORBIDITY; MORTALITY; SODIUM BALANCE;

EID: 0032405559     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000710     Document Type: Article

References (124)

1. Hosenpud JD et al. The Registry of the International Society for Heart and Lung Transplantation: Fourteenth Official Report - 1997. J Heart Lung Transplant 1997; 16: 691-712.
2. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987; 316: 1429-1435.
3. The SOLVD Investigators. Effect of Enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-691.
4. Swedberg K et al. Effects of early administration of enalapril on mortality in patients with acute myocardial infarction (CONSENSUS II). N Engl J Med 1992; 327: 678-684.
5. Pfeffer MA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival And Ventricular Enlargement trial. N Engl J Med 1992; 327: 669-677.
6. Valantine H, Schroeder JS. Recent advances in cardiac transplantation. N Engl J Med 1995; 333: 660-661.
7. Parameshwar J, Schofield P, Large S. Long term complications of cardiac transplantation. Br Heart J 1995; 74: 341-342.
8. Lee AH et al. Osteoporosis and bone morbidity in cardiac transplant recipients. Am J Med 1994; 96: 35-41.
9. Starling RC, Cody RJ. Cardiac transplant hypertension. Am J Cardiol 1990; 65: 106-111.
10. Sander M, Victor RG. Hypertension after cardiac transplantation: pathophysiology and management. Curr Opin Nephrol Hypertens 1995; 4: 443-451.
11. Singer DR, Jenkins GH. Hypertension in transplant recipients. J Hum Hypertens 1996; 10: 395-402.
12. Ventura HO, Mehra MR, Stapleton DD, Smart FW. Cyclosporine-induced hypertension in cardiac transplantation. Med Clin North Am 1997; 81: 1347-1357.
13. Ventura HO et al. Mechanisms of hypertension in cardiac transplantation and the role of cyclosporine. Curr Opin Cardiol 1997; 12: 375-381.
14. Thompson ME et al. New onset of hypertension following cardiac transplantation: a preliminary report and analysis. Transplant Proc 1983; 15 (Suppl 1): 2573-2577.
15. Matysek J, Piwowarska W. [Hypertension in patients after heart transplantation]. Przegl Lek 1995; 52: 565-568.
16. Ozdogan E et al. Factors influencing the development of hypertension following cardiac transplantation. J Heart Transplant 1990; 5: 548-553.
17. Baroud I et al. Long-term follow-up of heart transplant patients. Acta Cardiol 1996; 51: 315-325.
18. Guckelberger O et al. Cardiovascular risk factors in long-term follow-up after orthotopic liver transplantation. Clin Transplant 1997; 11: 60-65.
19. Martinelli L et al. Different results of cardiac transplantation in patients with ischemic and dilated cardiomyopathy. Eur J Cardiothorac Surg 1995; 11: 644-650.
20. Law CM et al. Initiation of hypertension in utero and its amplification throughout life. BMJ 1993; 306: 24-27.
21. Kannel WB, Belanger AJ. Epidemiology of Heart Failure. Am J Med 1991; 121: 951.
22. Pickering TG, Devereux R. Ambulatory monitoring of blood pressure as a predictor of cardiovascular risk. Am Heart J 1987; 114: 925-928.
23. Bevan AT, Honour AJ, Scott FG. Direct arterial pressure recording in unrestricted man. Clin Sci 1969; 36: 329-344.
24. Reeves RA, Shapiro AP, Thompson ME, Johnsen A-M. Loss of nocturnal decline in blood pressure following cardiac transplantation. Circulation 1986; 73: 401-408.
25. Cugini P et al. [Describing and interpreting systemic hypertension in heart transplantation with non-invasive arterial pressure monitoring]. Cardiologia 1996; 41: 653-659.
26. Cugini P et al. [Who are the "non-dippers": an insight from the ambulatory monitoring of arterial pressure in heart transplant patients]. Recenti Prog Med 1997; 88: 212-216.
27. Spallone V et al. Relationship between the circadian rhythms of blood pressure and sympathovagal balance in diabetic autonomic neuropathy. Diabetes 1993; 42: 1745-1752.
28. Bernardi L et al. Non-respiratory components of heart rate variability in heart transplant recipients: evidence of autonomic reinnervation. Clin Sci 1994; 86: 537-545.
29. De Marco T et al. Iodine-123 Meta-iodobenzylguanidine Scintigraphic assessment of the transplanted human heart: evidence of late reinnervation. J Am Coll Card 1995; 25: 927-931.
30. Ramaekers D et al. Heart rate variability in heart transplant recipients: evidence of reinnervation. Pace 1995; 18 (pt2): 1738.
31. Wilson RF et al. Evidence for structural sympathetic reinnervation after orthotopic cardiac transplantation in humans. Circulation 1991; 83: 1210.
32. Akosah K, Olsovsky M, Mohanty PK. Dobutamine stress-induced angina in patients with denervated cardiac transplants. Clinical and angiographic correlates. Chest 1995; 108: 695-700.
33. Fagard R, Macor F, Vanhaecke J. Signs of functional efferent reinnervation of the heart in patients after cardiac transplantation. Acta Cardiol 1995; 50: 369-380.
34. van de Borne P, Leeman M, Primo G, Degaute J-P. Reappearance of a normal circadian rhythm of blood pressure after cardiac transplantation. Am J Cardiol 1992; 69: 794-801.
35. Bracht C et al. Circadian variations of blood pressure and heart rate early and late after heart transplantation. Transplantation 1996; 62: 1187-1190.
36. Idema RN et al. Decreased circadian blood pressure variation up to three years after heart transplantation. Am J Cardiol 1994; 73: 1006.
37. Khot UN, Binkley PF, Haas GJ, Starling RC. Prospective study of the circadian pattern of blood pressure after heart transplantation. J Heart Lung Transplant 1996; 15: 350-359.
38. Jenkins GH et al. Is cardiac reinnervation in heart transplant recipients functionally significant? Insight from studies of diurnal blood pressure variability and cardiac mass. Transplant Proc 1997; 29: 571.
39. Hohage H et al. Influence of cyclosporine A and FK506 on 24 h blood pressure monitoring in kidney transplant recipients. Clin Nephrol 1996; 45: 342-344.
40. van den Dorpel MA et al. Cyclosporin A impairs the nocturnal blood pressure fall in renal transplant recipients. Hypertension 1996; 28: 304-307.
41. Marx MA, Gardner SF, Ketel BL. Diurnal blood pressure variation in kidney-pancreas transplant recipients. Am J Hypertens 1996; 9: 823-827.
42. Bunke M, Sloan R, Brier M, Ganzel B. An improved glomerular filtration rate in cardiac transplant recipients with once-a-day cyclosporine dosing [see comments]. Transplantation 1995; 59: 537-540.
43. Cugini P et al. [Hypertensive cardiac damage in heart transplantation. A noninvasive monitoring study of arterial pressure]. Recenti Prog Med 1996; 87: 460-465.
44. Angermann CE et al. [Circadian behavior of blood pressure and heart rate following orthotopic heart transplantation. Studies before and during antihypertensive therapy]. Z Kardiol 1989; 78: 228-235.
45. Singer DRJ et al. Blood pressure and endocrine responses to changes in dietary sodium intake following cardiac transplantation. Circulation 1994; 89: 1153-1189.
46. Singer DRJ et al. Raised plasma atrial natriuretic peptides in cardiac transplant recipients. Br Med J 1986; 293: 1391-1392.
47. Singer DRJ et al. Response to dynamic exercise in cardiac transplant recipients: implications for control of the sodium regulatory hormone atrial natriuretic peptide. Clin Sci 1990; 78: 159-163.
48. Wilkins MR et al. Effect of lower body positive pressure on blood pressure, plasma atrial natriuretic factor concentration, and sodium and water excretion in healthy volunteers and cardiac transplant recipients. Cardiovasc Res 1988; 22: 231-235.
49. Braith RW et al. Fluid homeostasis after heart transplantation: the role of cardiac denervation. J Heart Lung Transplant 1996; 15: 872-880.
50. Cugini P et al. Atrial natriuretic peptide in normotensive and hypertensive heart transplanted patients. Acta Cardiol 1996; 51: 252-258.
51. Hestin D et al. Relationship between blood pressure and renin, angiotensin II and atrial natriuretic factor after renal transplantation. Clin Nephrol 1997; 48: 98-103.
52. Freimark D et al. Atrial emptying with orthotopic heart transplantation using bicaval and pulmonary venous anastomoses: a magnetic resonance imaging study. J Am Coll Cardiol 1995; 25: 932-936.
53. Geny B et al. Atrial natriuretic factor secretion: a role for atrial systolic ejection force? Eur J Appl Physiol 1996; 72: 440-444.
54. Curtis JJ, Luke RG, Jones P, Diethelm AG. Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent. Am J Med 1988; 85: 134-138.
55. Bellet M et al. Systemic hypertension after cardiac transplantation: effect of cyclosporine on the reninangiotensin-aldosterone system. Am J Cardiol 1985; 56: 927-931.
56. Braith RW et al. Breakdown of blood pressure and body fluid homeostasis in heart transplant recipients. J Am Coll Cardiol 1996; 27: 375-383.
57. Andoh TF et al. Functional and structural characteristics of experimental FK 506 nephrotoxicity. Clin Exp Pharmacol Physiol 1995; 22: 646-654.
58. Heagerty AM, Bund SJ, Aalkjaer C. Effects of drug treatment on resistance arterial morphology in essential hypertension: direct evidence for structural remodelling of resistance vessels. Lancet 1988; ii: 1209-1212.
59. Katz AM. Angiotensin II: hemodynamic regulator or growth factor? [editorial]. J Molecular & Cellular Cardiol 1990; 22: 739-747.
60. Grainger DJ et al. Serum concentration of transforming growth factor-β is severely depressed in advanced atherosclerosis. Nature Medicine 1995; 1: 74-79.
61. Jenkins JT et al. Vascular remodelling in intramyocardial resistance vessels in hypertensive human cardiac transplant recipients. Heart 1997; 77: 353-356.
62. Julien J et al. Cyclosporin induced stimulation of the renin-angiotensin system after liver and heart transplantation. Transplantation 1993; 56: 885-891.
63. Ong AC et al. Effect of cyclosporin A on endothelin synthesis by cultured human renal cortical epithelial cells. Nephrol Dial Transplant 1993; 8: 748-753.
64. Cavero PG et al. Effects of orthotopic cardiac transplantation on peripheral vascular function in congestive heart failure: influence of cyclosporine therapy. Am Heart J 1994; 127: 1581-1587.
65. Hosenpud JD et al. The Registry of the International Society for Heart and Lung Transplantation - Twelfth Official Report - 1995. J Heart Lung Transplant 1995; 14: 805-815.
66. Carrier M, Tronc F, Stewart D, Pelletier LC. Dose-dependant effect of cyclosporin on renal artery resistance of dogs. Am J Physiol 1991; 261: H1791-H1796.
67. Levin ER. Endothelins. N Engl J Med 1995; 333: 356-363.
68. Abassi ZA, Pieruzzi F, Nakhoul F, Keiser HR. Effects of cyclosporin A on the synthesis, excretion, and metabolism of endothelin in the rat. Hypertension 1996; 27: 1140-1148.
69. Haynes WG, Clarke JG, Cockcroft JR, Webb DJ. Pharmacology of endothelin-1 in vivo in humans. J Cardiovasc Pharmacol 1991; 17 (Suppl 7): S284-S286.
70. Grieff FM, Loertsher R, Shoaib AS, Stewart DJ. Cyclosporin-induced elevation in circulating endothelin-1 in patients with solid organ transplants. Transplantation 1993; 56: 880-884.
71. Bloom IT, Bentley FR, Spain DA, Garrison RN. An experimental study of altered nitric oxide metabolism as a mechanism of cyclosporin-induced renal vasoconstriction. Br J Surg 1995; 82: 195-198.
72. Bartholomeusz B, Hardy KJ, Nelson AS, Phillips PA. Bosentan ameliorates cyclosporin A-induced hypertension in rats and primates. Hypertension 1996; 27: 1341-1345.
73. Bossaller C. Cyclosporin A inhibits endothelium-dependant vasodilatation and vascular prostacyclin production. Eur J Pharmacol 1989; 165: 165-169.
74. Solangi K et al. L-Arginine protects cyclosporin-induced blood pressure elevation in spontaneously hypertensive rats. Clin Res 1990; 38: 349A.
75. Marumo T et al. Cyclosporin A inhibits nitric oxide synthase induction in vascular smooth muscle cells. Hypertension 1995; 25: 764-768.
76. Morgan BJ, Lyson T, Scherrer U, Victor RG. Cyclosporin causes sympathetically mediated elevations in arterial pressure in rats. Hypertension 1991; 18: 458-466.
77. Grobecker HF, Riebel K, Wellenhofer T. Cyclosporine A-induced hypertension in SHR and WKY: role of the sympatho-adrenal system. Clin Exp Pharmacol Physiol Suppl 1995; 1: S94-S95.
78. Lyson T et al. Cyclosporine-and FK506-induced sympathetic activation correlates with calcineurin-mediated inhibition of T-cell signaling. Circ Res 1993; 73: 596-602.
79. Scherrer U et al. Cyclosporin causes sympathetic activation and hypertension after heart transplantation. N Engl J Med 1990; 323: 693-699.
80. Kaye D, Thompson J, Jennings G, Esler M. Cyclosporin therapy after cardiac transplantation causes hypertension and renal vasoconstriction without sympathetic activation. Circulation 1993; 88: 1101-1109.
81. Rundqvist B, Elam M, Eisenhofer G, Friberg P. Normalization of total body and regional sympathetic hyperactivity in heart failure after heart transplantation. J Heart Lung Transplant 1996; 15: 516-526.
82. Rundqvist B et al. Rapid fall in sympathetic nerve hyperactivity in patients with heart failure after cardiac transplantation. J Card Fail 1997; 3: 21-26.
83. Andreassen AK, Simonsen S, Bjornerheim R, Kvernebo K. Attenuated microvascular perfusion and reactivity in cardiac transplant recipients treated with cyclosporine. Int J Microcirc Clin Exp 1995; 15: 117-124.
84. Conte G et al. Acute cyclosporin renal dysfunction reversed by dopamine infusion in healthy subjects. Kidney Int 1989; 36: 1086-1092.
85. Chervu I, Karubian F, Campese V. The role of endothelial factors; cyclosporin and erythropoietin in hypertension in chronic renal failure. Current Opinion in Cardiol 1992; 7: 776-781.
86. Garr MD. Cyclosporin augments renal but not systemic vascular reactivity. Am J Physiol 1990; 258: F211-F217.
87. Waser M et al. Irreversibility of cyclosporin-induced renal function impairment in heart transplant recipients. J Heart Lung Transp 1993; 12: 846-850.
88. Myers BD et al. Cyclosporin associated chronic nephropathy. N Engl J Med 1984; 311: 699.
89. Andoh TF, Burdmann EA, Bennett WM. Nephrotoxicity of immunosuppressive drugs: experimental and clinical observations. Semin Nephrol 1997; 17: 34-45.
90. Falkenhain ME, Cosio FG, Sedmak DD. Progressive histologic injury in kidneys from heart and liver transplant recipients receiving cyclosporine. Transplantation 1996; 62: 364-370.
91. Ader JL et al. Renal functional reserve in kidney and heart transplant recipients. J Am Soc Nephrol 1996; 7: 1145-1152.
92. Bantle JP, Boudreau RJ, Ferris TF. Suppression of plasma renin activity by cyclosporine. Am J Med 1987; 83: 59-64.
93. Sehested J et al. Effects of acute administration of cyclosporin on levels of cardiovascular hormones in heart transplant recipients. Am J Cardiol 1993; 72: 484-486.
94. White M et al. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients. J Heart Lung Transplant 1997; 16: 787-794.
95. Charnick SB et al. Description of blood pressure changes in patients beginning cyclosporin A therapy. Ther Drug Monit 1997; 19: 17-24.
96. Armitage JM et al. Preliminary experience with FK506 in thoracic transplantation. Transplantation 1991; 52: 164-167.
97. Bennett WM. The nephrotoxicity of immunosuppressive drugs. Clin Nephrol 1995; 43 (Suppl 1): S3-S7.
98. Golbaekdal K, Nielsen CB, Pedersen EB. The acute effects of FK-506 on renal haemodynamics, water and sodium excretion and plasma levels of angiotensin II, aldosterone, atrial natriuretic peptide and vasopressin in pigs. J Pharm Pharmacol 1996; 48: 1174-1179.
99. Takeda Y et al. Effect of FK 506 on the expression of endothelin receptor mRNA in the vasculature. J Cardiovasc Pharmacol 1995; 26 (Suppl 3): S290-S292.
100. Asante Korang A et al. Experience of FK506 immune suppression in pediatric heart transplantation: a study of long-term adverse effects. J Heart Lung Transplant 1996; 15: 415-422.
101. Swenson JM, Fricker FJ, Armitage JM. Immunosuppression switch in pediatric heart transplant recipients: cyclosporine to FK 506. J Am Coll Cardiol 1995; 25: 1183-1188.
102. Armitage JM et al. A decade (1982 to 1992) of pediatric cardiac transplantation and the impact of FK 506 immunosuppression. J Thorac Cardiovasc Surg 1993; 105: 464-472.
103. Egawa H et al. FK506 conversion therapy in pediatric liver transplantation. Transplantation 1994; 57: 1169-1173.
104. Ellis D. Clinical use of tacrolimus (FK-506) in infants and children with renal transplants. Pediatr Nephrol 1995; 9: 487-494.
105. Pham SM et al. A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term results. J Thorac Cardiovasc Surg 1996; 111: 764-772.
106. Rinaldi M et al. FK506 effectiveness in reducing acute rejection after heart transplantation: a prospective randomized study. J Heart Lung Transplant 1997; 16: 1001-1010.
107. Fung JJ, Starzl TE. FK506 in solid organ transplantation. Ther Drug Monit 1995; 17: 592-595.
108. Williams R et al. Two-year data from the European multicentre tacrolimus (FK506) liver study. Transpl Int 1996; 9 (Suppl 1): S144-S150.
109. Textor SC et al. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation 1993; 55: 1332-1339.
110. McDiarmid SV et al. A comparison of renal function in cyclosporine- and FK-506-treated patients after primary orthotopic liver transplantation. Transplantation 1993; 56: 847-853.
111. Olivari MT et al. Triple-drug immunosuppression with steroid discontinuation by six months after heart transplantation. J Heart Lung Transplant 1995; 14: 127-135.
112. Taler SJ et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. Transplantation 1996; 62: 1588-1592.
113. Benediktsson R, Edwards CR. Apparent mineralocorticoid excess. J Hum Hypertens 1994; 8: 371-375.
114. McKoy RC et al. Left ventricular hypertrophy in cyclosporine-induced systemic hypertension after cardiac transplantation. Am J Cardiol 1988; 62: 1140-1142.
115. Farge D et al. Effect of hypertension on the renal and cardiac functions of patients with heart transplantation [Fre]. Archives Des Maladies Du Coeur Et Des Vaisseaux 1990; 83: 1129-1133.
116. Julien J et al. Mid-term echographic evaluation of systolic function after cardiac transplantation [Fre]. Archives Des Maladies Du Coeur Et Des Vaisseaux 1990; 83: 495-500.
117. Larson DF, Copeland JG, Russell DH. Catecholamine-induced cardiac hypertrophy in a denervated, hemodynamically non-stressed heart transplant. Life Sci 1985; 36: 2477-2489.
118. Milano CA et al. Myocardial expression of a constitutively active alpha 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. PNAS USA 1994; 91: 10109-10113.
119. Kardami E. Stimulation and inhibition of cardiac myocyte proliferation in vitro. Molecular & Cellular Biochem 1990; 92: 129-135.
120. Globits S et al. Assessment of early left ventricular remodeling in orthotopic heart transplant recipients with cine magnetic resonance imaging: potential mechanisms. J Heart Lung Transplant 1997; 16: 504-510.
121. Missouris CG, Buckenham T, Cappuccio FP, MacGregor GA. Renal artery stenosis: a common and important problem in patients with peripheral vascular disease. Am J Med 1994; 96: 10-14.
122. Arbustini E et al. Factors increasing the risk of allograft vascular disease in heart transplant recipients. G Ital Cardiol 1997; 27: 985-999.
123. Barbir M et al. Determinants of transplant-related coronary calcium detected by ultrafast computed tomography scanning. Am J Cardiol 1997; 79: 1606-1609.
124. Jenkins GH, Grieve L, Yacoub MH, Singer DRJ. Left ventricular mass and diurnal variation in blood pressure with time after cardiac transplant. J Hum Hypertens 1996; 10: 413-414.